Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

Dorward J. et al, (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Yu L-M. et al, (2021), Lancet

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.

Hinks TSC. et al, (2021), Lancet respir med

Drug Discovery and Development Technology in Transition

Hill RG. and Richards D., (2021)

Multiple Endocrine Neoplasia Type 1 in Children and Adolescents: Clinical Features and Treatment Outcomes

SHARIQ O. and RICHARDS D., (2021), Surgery

Base of thumb osteoarthritis (BTOA) in UK interface services-a cohort and survey based study to assess current practice.

Dean BJF. et al, (2020), Rheumatology (oxford)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Feldmann M. et al, (2020), Lancet, 395, 1407 - 1409

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Robinson PC. et al, (2020), The lancet rheumatology

Identification, preclinical profile, and clinical proof of concept of a novel palindromic orally bio-available pro-drug of miridesap

RICHARDS D. et al, (2019), British journal of pharmacology

Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.

Deane AM. et al, (2018), Jpen j parenter enteral nutr, 42, 949 - 959

A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.

Marrinan SL. et al, (2018), Mov disord, 33, 329 - 332

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB. et al, (2018), Sci transl med, 10

Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy.

Babinsky VN. et al, (2017), Endocrinology, 158, 2486 - 2502

Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study.

Fernando D. et al, (2017), Ebiomedicine, 22, 249 - 255

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.

Hegade VS. et al, (2017), Lancet, 389, 1114 - 1123

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H. et al, (2016), Neuropsychopharmacology, 41, 2647 - 2657

The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.

Chapman MJ. et al, (2016), Crit care, 20

BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.

Hegade VS. et al, (2016), Bmc gastroenterol, 16

The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.

Hellström PM. et al, (2016), Br j pharmacol, 173, 1768 - 1777

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Pepys MB. et al, (2015), Blood, 126

Load More

Include forthcoming?